Executive Summary
The PARTNER 3 health-status substudy in JACC reframes the low-risk TAVR-vs-SAVR debate: mortality is a wash at seven years, but TAVR patients feel meaningfully better at one month and hold that KCCQ advantage out to two years before curves converge. The benefit was largest in reduced-EF patients, with no sex or AF interaction — a finding that tightens the case for TAVR as first-line in symptomatic low-risk patients closer to the ESC 2025 threshold of 70 than to the ACC/AHA 2020 threshold of 65, but only for balloon-expandable Sapien 3 recipients. A separate propensity-matched analysis (N=572) in Journal of Cardiology muddies the valve-choice conversation for mixed AS: self-expanding valves delivered lower gradients but higher stroke and vascular complication rates. A meta-analysis of 36 studies and 272,390 TAVR patients confirms conventional risk scores (STS C-index 0.648) remain mediocre — machine learning models (0.705) are pulling ahead, which complicates how we counsel borderline patients.
- PARTNER 3 health-status substudy: TAVR patients recovered faster and reported higher KCCQ scores through 2 years; reduced-EF subgroup saw the largest sustained benefit (JACC via Cardiovascular Business).
- Mixed AS with moderate-or-greater AR: SEV beat BEV on 30-day and 1-year mean gradients (7.9 vs 12.1 mmHg) but doubled stroke and vascular complication rates (Journal of Cardiology).
- Machine learning models outperform STS, EuroSCORE II, and TVT risk calculators for post-TAVR mortality (C-index 0.705 vs 0.648) across 272,390 patients (Frontiers in Cardiovascular Medicine).
- A single-case buddy-balloon bailout rescued failed valve crossing in extreme calcification — severe LVOT/annular calcium remains a SAVR-favoring feature per ESC 2025 (Cureus).
- Medtronic dropped 2.1% on a flat-to-weak tape while Edwards gained 1.35% — divergence tracks with today's PARTNER 3 tailwind for the Sapien franchise (Cardiovascular Business).
What to watch: Edwards' Q3 earnings on October 29 — the first full quarter to reflect any prescribing-pattern shift following the PARTNER 3 seven-year mortality equipoise data from TCT 2025.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The PARTNER 3 health-status substudy in JACC is the day's most consequential paper. With mortality equipoise established at seven years, quality-of-life recovery becomes the tiebreaker. TAVR patients scored materially higher on KCCQ at one month and held the lead through two years before both arms converged. The reduced-EF signal deserves attention — this is precisely the subgroup where the ESC 2025 guideline lowered the TAVI-preferred age threshold to 70. Edwards funded the analysis and results apply only to Sapien 3; a self-expanding comparator would tell a different story. ACC/AHA 2020 still recommends SAVR for symptomatic severe AS in patients under 65 with tricuspid anatomy, and shared decision-making from 65 to 80. The PARTNER 3 QoL data sharpen the shared-decision conversation — particularly for patients who prioritize rapid return to function — without overturning that framework.
For mixed AS (severe AS with ≥moderate AR, a population excluded from most pivotal TAVR trials), the propensity-matched single-center analysis (N=572 matched, 12-year retrospective) found SEV delivered better hemodynamics but worse stroke and vascular complications at 30 days; long-term mortality equalized. Neither ACC/AHA 2020 nor ESC 2025 endorses TAVR as preferred in mixed AS — SAVR eliminates both lesions in one operation and carries no equivalent stroke-complication tradeoff in this anatomy. Single-center, retrospective, propensity-matched: hypothesis-generating, not practice-changing.
The systematic review of TAVR mortality prediction models should discipline how we present risk to patients. STS gives a C-index of 0.648, EuroSCORE II 0.615, and the ESC's 4% surgical-risk threshold for SAVR preference rests on tools with only modest discrimination. ML models at 0.705 outperform but are not yet in clinical workflow.
Tricuspid Valve (TriClip, TTVR)
A new real-world tricuspid TEER post-market study was announced to examine real-world use — no results yet, but the study design matters. ESC 2025 elevated transcatheter tricuspid treatment to Class IIa (LOE A) for symptomatic severe TR in high-risk patients, based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. ACC/AHA 2020 predates all three trials and offers no recommendation on transcatheter TR.
The gap between the two guidelines here is the widest in structural heart. US operators are treating patients under a Class IIa European recommendation with no US guideline analog — the next ACC/AHA update cannot come soon enough. On the surgical side, ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I, reflecting the parallel recognition that late referral — not the operation itself — drives the historical 8–20% isolated TV surgery mortality.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. The PARTNER 3 QoL substudy is the closest thing — and its message sits uneasily against the durability caveat ESC 2025 explicitly names: TAVI durability data through 10 years look comparable to SAVR, but selection bias and variable SVD definitions temper confidence. A 73.5-year-old who lives 15 or more years post-procedure remains in territory where SAVR's durability track record has decades of runway that TAVR does not.
The mixed-AS SEV-vs-BEV data (Journal of Cardiology) warrants flagging against the surgical comparator the paper omits: for patients with severe AS plus ≥moderate AR, SAVR remains straightforward and eliminates both lesions in one operation. Neither ACC/AHA 2020 nor ESC 2025 endorses TAVR as preferred in mixed AS.
Device & Technology
A multitask deep learning model (BAMNet) for intraoperative fluoroscopic aortic root segmentation and landmark localization hit real-time inference at 63 FPS with sub-3mm landmark error across 2,895 frames from 83 patients. Single-center, retrospective, and not yet prospectively validated — but the direction is clear: image-guided TAVI will move toward AI-augmented annular sizing and coronary-ostia mapping over the next 2–3 years. Whether that reduces PVL and PPM in real-world practice is the outcome to watch.
A case report of buddy-balloon-assisted bailout for a 26mm balloon-expandable THV that would not cross a heavily calcified native valve is a reminder that severe LVOT and annular calcium remains a SAVR-favoring anatomy in ESC 2025 — technique advances don't erase the underlying biology.
Clinical Trial Updates
The Myoflame-19 trial (Nature Communications, N=279) tested losartan plus prednisolone for post-COVID cardiac inflammation and missed its primary LVEF endpoint (between-group difference 0.74 pp, p=0.10). Secondary symptom and imaging measures trended favorably but confidence intervals crossed null. Not a valve trial, but relevant: post-COVID inflammatory cardiomyopathy is an underappreciated comorbidity in older TAVR candidates.
Industry & Market
The Kaweah Health 500th TAVR milestone and the expansion of structural heart programs in India both point at the same story: the global TAVR volume curve is steepening in mid-sized US regional centers and in emerging Asian markets. That is a top-line story for EW and MDT, but also a training-and-quality story — the mixed-AS and calcification data today reinforce that lower-volume centers face higher-complexity cases without proportionate operator experience.
Financial Analysis
Edwards' 1.35% gain on July 30 coincides with the PARTNER 3 JACC publication — a favorable QoL data point for the Sapien franchise arrives just as the low-risk expansion narrative had been leaning on the seven-year mortality equipoise. Medtronic's 2.1% decline and 15% six-month drawdown reflect broader pipeline concerns unrelated to today's data, but the divergence illustrates how single-substudy readouts still move sentiment in structural heart. Multiple insider sales at EW (Markowitz, others) are routine 10b5-1 activity and don't warrant reading into.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $86.92 (+1.35%); 6-month +5.17%; 52-week range $72.30–$96.29
- Market cap $50.0B; P/E trailing 51.13, forward 25.75; beta 0.85
- Analyst target $100.96 (26 analysts); consensus buy
- Next earnings October 29 (EPS est $0.74; Rev est $1.68B)
Today's PARTNER 3 QoL substudy is a tailwind for the Sapien franchise ahead of Q3 earnings. The stock has recovered from Q1 weakness but remains below analyst target — the durability question at 10+ years remains the ceiling on the multiple.
Medtronic (MDT)
- Close: $85.71 (-2.09%); 6-month -15.11%; 52-week range $73.31–$106.33
- P/E trailing 23.48, forward 13.37; beta 0.58
- Analyst target $98.44 (25 analysts); consensus buy
- Next earnings September 1 (EPS est $1.39; Rev est $9.55B)
MDT's structural heart franchise (Evolut) is not the primary drag — broader diversification and diabetes exposure are. The SEV-associated stroke and vascular signal in mixed AS is a data point operators will factor into valve selection, and self-expanding platforms carry that headwind.
Abbott (ABT)
- Close: $105.61 (-2.21%); 6-month -2.17%; 52-week range $81.97–$137.49
- Market cap $182.7B; P/E trailing 34.97, forward 17.42; beta 0.61
- Analyst target $118.42 (24 analysts); consensus buy
- Next earnings October 14 (EPS est $1.42; Rev est $12.99B)
ABT owns MitraClip and TriClip — the announced real-world tricuspid TEER study today extends the post-TRILUMINATE evidence base that the Class IIa ESC 2025 recommendation rests on. Larger real-world datasets are how ABT defends the Class IIa position into eventual ACC/AHA adoption.
Boston Scientific (BSX)
- Close: $46.00 (-0.09%); 6-month -49.93%; 52-week range $42.20–$109.50
- Market cap $68.4B; P/E trailing 18.62, forward 13.27
- Analyst target $64.28 (29 analysts); consensus buy
- Next earnings October 21 (EPS est $0.80; Rev est $5.25B)
The 6-month drawdown of nearly 50% reflects issues outside structural heart. The Acurate neo2 discontinuation removed BSX from the aortic TAVR competitive field; the tricuspid pipeline remains the structural heart story to watch.
Anteris Technologies (AVR.AX)
- Close: A$11.29 (unchanged); 6-month +35.21%; 52-week range A$5.00–A$15.47
- Market cap A$1.1B; forward P/E -5.18; beta 0.73
- Analyst target A$13.00 (1 analyst)
DurAVR clinical progression remains the driver. The pre-shaped balloon-expandable single-piece design is aimed squarely at the durability question today's PARTNER 3 update sidesteps — first-in-human data will determine whether the market cap is defensible.
Market outlook: The valve sector is bifurcating. EW and ABT — with clear structural heart franchises tied to today's evidence base — trade closer to fundamentals. MDT and BSX carry diversification drag that decouples them from the tricuspid and low-risk TAVR data cycles. The next inflection point is Edwards' Q3 print on October 29.
The PARTNER 3 QoL data closes one loop and opens another: mortality equipoise plus a clear early-recovery advantage for TAVR forces the guideline conversation onto durability and reintervention planning. The next ACC/AHA update needs to incorporate PARTNER 3 seven-year data, EARLY TAVR, and the tricuspid TEER evidence — the current five-year-old US framework is increasingly out of step with what operators are doing in clinic.